Je was op zoek naar: ulcerative colitis (Frans - Engels)

active ulcerative colitis
treatment of active ulcerative colitis

treatment of active ulcerative colitis
· treatment of active ulcerative colitis

bovine ulcerative mammillitis virus
bovine herpesvirus 02

il est employé dans le traitement du colitis ulcerative.
it is used in the treatment of ulcerative colitis.

quels sont les symptômes de la c. difficile colitis?
what are the symptoms of c. difficile colitis?

studies of the induction and regulation of colitis in a mouse model
university health network (toronto)

quels sont les symptômes de la c. difficile colitis?
what are the symptoms of c. difficile colitis?

preparations pharmaceutiques pour le traitement de colitis ulcerosa et de colitis granulomatosa.
pharmaceutical preparations for the treatment of colitis ulcerosa and colitis granulomatosa.

rapamycin pour le traitement de morbus crohn, de colitis ulcereux et proctitis ulcereux
rapamycin for the treatment of crohn's disease, ulcerative colitis or ulcerative proctitis

« european guideline for the management of tropical genitor-ulcerative diseases.
european guideline for the management of tropical genitor-ulcerative diseases.

a severe outbreak of escherichia coli o157:h7 associated hemorrhagic colitis in a nursing home.
an outbreak of acute nonbacterial gastroenteritis in a nursing home.

peptides lineares and cycliques pour le traitement ou la prevention de la maladie de crohn et/ou de la colite ulcerative
linear and cyclic peptides for treatment or prevention of crohn's disease and/or ulcerative colitis

first recognized community outbreak of haemorrhagic colitis due to verotoxin-producing escherichia coli o157-h7 in the uk.
first recognized community outbreak of haemorrhagic colitis due to verotoxin-producing escherichia coli o157:h7 in the uk.

c.n. bernstein, j.f. blanchard, p. rawsthorne et al., « epidemiology of crohn’s disease and ulcerative colitis in a central canadian province:
bio med central gastroenterology 2002; 2(1): 1.

À la semaine 8, la rémission clinique mesurée par le score pucai (paediatric ulcerative colitis activity index) était de 33,3 % (17/51).
clinical remission at week 8 was 33.3% (17/51) as measured by the paediatric ulcerative colitis activity index (pucai) score.

traditionnellement, l'utilisation d'antibiotiques est souvent considérée comme le facteur le plus important pour le développement de la c. difficile colitis.
traditionally, antibiotic use is often considered the most important factor for the development of c. difficile colitis.

r.e. andersonn, g. olaison, c. tysk et al., « appendectomy and protection against ulcerative colitis », the new england journal of medicine, 344(11), 2001, p.
the italian group for the study of colon and rectum (gisc). italian journal of gastroenterology and hepatology 1997; 29(3): 208-11.

compositions et methodes de traitement de maladies ulceratives, de brulures, et d'etats associes
compositions and methods of treatment of ulcerating diseases, burns, and related conditions